company background image
6NQ logo

Synthaverse DB:6NQ Stock Report

Last Price

€0.93

Market Cap

€69.8m

7D

-1.2%

1Y

-5.0%

Updated

01 Nov, 2024

Data

Company Financials

6NQ Stock Overview

A pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.

6NQ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health2/6
Dividends0/6

Synthaverse S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Synthaverse
Historical stock prices
Current Share Pricezł0.93
52 Week Highzł1.28
52 Week Lowzł0.63
Beta1.13
11 Month Change-1.91%
3 Month Change-14.67%
1 Year Change-4.98%
33 Year Change-51.24%
5 Year Changen/a
Change since IPO-78.98%

Recent News & Updates

Recent updates

Shareholder Returns

6NQDE BiotechsDE Market
7D-1.2%-0.4%-1.8%
1Y-5.0%-14.9%13.2%

Return vs Industry: 6NQ exceeded the German Biotechs industry which returned -15.2% over the past year.

Return vs Market: 6NQ underperformed the German Market which returned 16.1% over the past year.

Price Volatility

Is 6NQ's price volatile compared to industry and market?
6NQ volatility
6NQ Average Weekly Movement4.3%
Biotechs Industry Average Movement6.4%
Market Average Movement5.0%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6NQ has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 6NQ's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1944239Mieczyslaw Starkowiczwww.synthaverse.pl

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma.

Synthaverse S.A. Fundamentals Summary

How do Synthaverse's earnings and revenue compare to its market cap?
6NQ fundamental statistics
Market cap€69.75m
Earnings (TTM)€566.92k
Revenue (TTM)€13.15m

123.0x

P/E Ratio

5.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6NQ income statement (TTM)
Revenuezł57.35m
Cost of Revenuezł22.61m
Gross Profitzł34.74m
Other Expenseszł32.27m
Earningszł2.47m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 20, 2024

Earnings per share (EPS)0.035
Gross Margin60.57%
Net Profit Margin4.31%
Debt/Equity Ratio69.4%

How did 6NQ perform over the long term?

See historical performance and comparison